Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03961516 · ClinicalTrials.gov registry record
Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis
A clinical trial, sponsored by University Hospitals Cleveland Medical Center.
- Completed
- Registry status
- 34
- Enrollment target
NCT03961516 is a clinical trial that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 34 participants.
The verdict
NCT03961516 has completed, sponsored by University Hospitals Cleveland Medical Center.
- COMPLETED
- Registry status
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the utility of a continuous glucose monitor device (CGM) in screening for cystic fibrosis related diabetes. The investigators will also study how fat deposition in the pancreas and liver impacts insulin production and response, as measured by a frequently sampled oral glucose tolerance test.
Interventions
- DEVICE Frequently Sampled Oral Glucose Tolerance Test and CGM
- RADIATION MRI Pancreas and Liver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2021-08-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03961516
The ClinicalTrials.gov registry entry for NCT03961516 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Frequently Sampled Oral Glucose Tolerance Test and CGM is the first listed.
NCT03961516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03961516 about?
NCT03961516 is a clinical study titled "Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis". The purpose of this study is to investigate the utility of a continuous glucose monitor device (CGM) in screening for cystic fibrosis related diabetes. The investigators will also study how fat deposition in the pancreas and liver impacts insulin production and response, as measured by a frequently ...
What is the current status of trial NCT03961516?
This trial is currently completed. The enrollment target is 34 participants. The study started on 2019-05-01. Estimated completion is 2021-08-30.
What interventions are being tested in trial NCT03961516?
The interventions under investigation include: Frequently Sampled Oral Glucose Tolerance Test and CGM (DEVICE), MRI Pancreas and Liver (RADIATION).
Who is sponsoring clinical trial NCT03961516?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.